← Leaderboards
Andrew John Shepherd
University Of Tx Md Anderson Can Ctr
$7,386,853
Attributed
$14,431,681
Total exposure
9
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2019–25$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,431,681 · 9
By mechanism
R01$6,162,288 · 4
RM1$4,618,885 · 1
UH3$1,940,013 · 1
UG3$1,302,218 · 2
R61$408,277 · 1
Top collaborators
- Vadim Cherezov5 shared
- Vsevolod Katritch5 shared
- Susruta Majumdar5 shared
- Peter M Grace4 shared
- Meaghan C Creed1 shared
- Simon Haroutounian1 shared
- Cobi J Heijnen1 shared
- Chenyang Lu1 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Hui-Lin Pan$27,634,836
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingPainCellsPre-ClinicalPharmaceutical PreparationsNeuronsAffectPeripheral NervesNovel StrategiesChronic PainBrainAfferent NeuronsNeuroimmuneIn VitroChemotherapyInnovationSide EffectMouse ModelResolutionPeripheralPain ManagementHypersensitivityProductionIn Vivo
Grant awards (17)
Development of Angiotensin AT2 inhibitors for neuropathic pain relief$818,360
UG3 · FY2025 · NS
Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes$459,060
R01 · FY2025 · DK · contact PI
Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy$408,277
R61 · FY2025 · NS · contact PI
Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes$109,933
R01 · FY2025 · DK · contact PI
IMPETUS: Integrated Mechanisms, Phenotypes, and Translational Underpinnings of Chronic Pain after Surgery$4,618,885
RM1 · FY2024 · NS
Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment$675,862
R01 · FY2024 · NS · contact PI
Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes$480,845
R01 · FY2024 · DK · contact PI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$607,440
UH3 · FY2023 · NS
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$359,431
R01 · FY2023 · CA
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$647,556
UH3 · FY2022 · NS
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$1
R01 · FY2022 · CA
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$685,017
UH3 · FY2021 · NS
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$366,766
R01 · FY2021 · CA
Validation of Fibroblast-Derived PI16 as a Novel Target for pain Treatment$2,908,421
R01 · FY2020 · NS · contact PI
Non-addictive Angiotensin AT2 inhibitors for neuropathic pain relief$483,858
UG3 · FY2020 · NS
Mesenchymal Stem Cells to Repair Chemobrain$402,051
R01 · FY2020 · CA
PQ12 Targeting HDAC6 for Chemotherapy-Induced Neuropathy and Chemobrain$399,918
R01 · FY2019 · CA